1
|
Tütüncü S, Olma M, Kunze C, Dietzel J, Schurig J, Fiessler C, Malsch C, Haas TE, Dimitrijeski B, Doehner W, Hagemann G, Hamilton F, Honermann M, Jungehulsing GJ, Kauert A, Koennecke HC, Mackert BM, Nabavi D, Nolte CH, Reis JM, Schmehl I, Sparenberg P, Stingele R, Völzke E, Waldschmidt C, Zeise-Wehry D, Heuschmann PU, Endress M, Haeusler KG. Off-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: results of the prospective multicenter Berlin Atrial Fibrillation Registry. J Neurol 2022; 269:470-480. [PMID: 34718884 PMCID: PMC8739306 DOI: 10.1007/s00415-021-10866-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Revised: 10/17/2021] [Accepted: 10/18/2021] [Indexed: 11/26/2022]
Abstract
AIMS We aimed to analyze prevalence and predictors of NOAC off-label under-dosing in AF patients before and after the index stroke. METHODS The post hoc analysis included 1080 patients of the investigator-initiated, multicenter prospective Berlin Atrial Fibrillation Registry, designed to analyze medical stroke prevention in AF patients after acute ischemic stroke. RESULTS At stroke onset, an off-label daily dose was prescribed in 61 (25.5%) of 239 NOAC patients with known AF and CHA2DS2-VASc score ≥ 1, of which 52 (21.8%) patients were under-dosed. Under-dosing was associated with age ≥ 80 years in patients on rivaroxaban [OR 2.90, 95% CI 1.05-7.9, P = 0.04; n = 29] or apixaban [OR 3.24, 95% CI 1.04-10.1, P = 0.04; n = 22]. At hospital discharge after the index stroke, NOAC off-label dose on admission was continued in 30 (49.2%) of 61 patients. Overall, 79 (13.7%) of 708 patients prescribed a NOAC at hospital discharge received an off-label dose, of whom 75 (10.6%) patients were under-dosed. Rivaroxaban under-dosing at discharge was associated with age ≥ 80 years [OR 3.49, 95% CI 1.24-9.84, P = 0.02; n = 19]; apixaban under-dosing with body weight ≤ 60 kg [OR 0.06, 95% CI 0.01-0.47, P < 0.01; n = 56], CHA2DS2-VASc score [OR per point 1.47, 95% CI 1.08-2.00, P = 0.01], and HAS-BLED score [OR per point 1.91, 95% CI 1.28-2.84, P < 0.01]. CONCLUSION At stroke onset, off-label dosing was present in one out of four, and under-dosing in one out of five NOAC patients. Under-dosing of rivaroxaban or apixaban was related to old age. In-hospital treatment after stroke reduced off-label NOAC dosing, but one out of ten NOAC patients was under-dosed at discharge. CLINICAL TRIAL REGISTRATION NCT02306824.
Collapse
Affiliation(s)
- Serdar Tütüncü
- Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Manuel Olma
- Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
- Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Claudia Kunze
- Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Joanna Dietzel
- Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Johannes Schurig
- Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Cornelia Fiessler
- Institute of Clinical Epidemiology and Biometry, University Würzburg, Würzburg, Germany
| | - Carolin Malsch
- Institute of Clinical Epidemiology and Biometry, University Würzburg, Würzburg, Germany
- Comprehensive Heart Failure Center, Clinical Trial Centre Würzburg, University of Würzburg, University Hospital Würzburg, Würzburg, Germany
| | - Tobias Eberhard Haas
- Institute of Clinical Epidemiology and Biometry, University Würzburg, Würzburg, Germany
| | | | - Wolfram Doehner
- Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
- BCRT-Berlin Institute of Health Center for Regenerative Therapies, and Department of Cardiology (Virchow Klinikum), Charité-Universitätsmedizin Berlin, German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany
| | - Georg Hagemann
- Department of Neurology, Helios Klinik Berlin-Buch, Berlin, Germany
| | - Frank Hamilton
- Department of Neurology, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany
| | - Martin Honermann
- Department of Neurology, Vivantes Klinikum Spandau, Berlin, Germany
| | | | - Andreas Kauert
- Department of Neurology, Evangelisches Krankenhaus Königin Elisabeth Herzberge, Berlin, Germany
| | | | | | - Darius Nabavi
- Department of Neurology, Vivantes Klinikum Neukölln, Berlin, Germany
| | - Christian H Nolte
- Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
- Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
- German Center for Cardiovascular Diseases (DZHK), Partner site Berlin, Berlin, Germany
- Berlin Institute of Health (BIH), Berlin, Germany
| | - Joschua Mirko Reis
- Institute of Clinical Epidemiology and Biometry, University Würzburg, Würzburg, Germany
| | - Ingo Schmehl
- Department of Neurology, BG Klinikum Unfallkrankenhaus Berlin, Berlin, Germany
| | - Paul Sparenberg
- Department of Neurology, BG Klinikum Unfallkrankenhaus Berlin, Berlin, Germany
| | - Robert Stingele
- Department of Neurology, German Red Cross Hospital Berlin Köpenick, Berlin, Germany
| | - Enrico Völzke
- Department of Neurology, Schlosspark-Klinik Berlin, Berlin, Germany
| | | | | | - Peter U Heuschmann
- Institute of Clinical Epidemiology and Biometry, University Würzburg, Würzburg, Germany
- Comprehensive Heart Failure Center, Clinical Trial Centre Würzburg, University of Würzburg, University Hospital Würzburg, Würzburg, Germany
| | - Matthias Endress
- Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
- Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE), Partner site Berlin, Berlin, Germany
- German Center for Cardiovascular Diseases (DZHK), Partner site Berlin, Berlin, Germany
- Berlin Institute of Health (BIH), Berlin, Germany
| | | |
Collapse
|
2
|
Sennblad B, Endress M, Bremer B. Morphology and molecular data in phylogenetic fraternity: the tribe Wrightieae (Apocynaceae) revisited. Am J Bot 1998; 85:1143. [PMID: 21684999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The monophyly and classification of the tribe Wrightieae of the subfarnily Apocynoideae (Apocynaceae) are cladistically investigated. Nine taxa from the Wrightieae sensu Leeuwenberg, nine from other Apocynoideae sensu lato (s.I., including two from the traditional Asclepiadaceae), and two outgroup taxa from the Plumerioideae (Apocynaceae) were scored for rcbL sequence data and morphological data, mainly floral characters, and analyzed using successive weighting parsimony analysis. The Wrightieae sensu Leeuwenberg are shown to be largely paraphyletic, the constituent taxa being dispersed among four monophyletic clades. Previously not suggested relationships indicated by the study are the association of Pachypodium with Funtumia, Holarrhena, and Mascarenhasia and the position of Beaumontia close to Trachelospermum. A reclassification of the Wrightieae is discussed, in which three of the identified clades are recognized as tribes, the Wrightieae sensu stricto (s.s.), the Nerieae, and the Malouetieae. The support for the Wrightieae s.s. is very strong, as evaluated with Bremer support and bootstrap analysis. The Malouetieae are also strongly supported, but the Nerieae less so. Using Potential morphological synapomorphies identified in the study, circumscription of the tribes is discussed. A potential pseudogene of rcbL is reported tot Beaumontia.
Collapse
|
4
|
Abstract
All CI chondrites are regolith breccias consisting of various types of chemically and mineralogically distinct mineral and lithic fragments (or units). In the CI chondrite Ivuna, for example, four different lithological units were identified and are referred to as lithology I, II, III, and IV. So far, lithologies III and IV have been identified in Orgueil as well. It appears that at least Ivuna and Orgueil consist of the same basic lithologies in different proportions. Carbonates in CIs occur as individual grains within such lithic units or exist as large fragments between them. Carbonate fragments are remnants of former carbonate veins and, in contrast to individual carbonate grains, are not genetically linked to lithological units. Four different types of carbonates (dolomite, breunnerite, calcite, siderite) occur in CIs and they constitute, on average, 5 vol% of each studied section. In this study, carbonates in the CI chondrites Orgueil, Ivuna, Alais, and Tonk were studied petrographically, mineralologically, and chemically. The results clearly indicate that, in contrast to most previous studies, compositional differences exist between dolomites within and among CI chondrites. From these differences it can be derived that (1) several episodes of alteration occurred on the CI parent body, (2) physicochemical conditions during carbonate formation must have been different among CIs, and (3) CI carbonates obviously were formed at low temperatures in equilibrium with surrounding fluid(s). While local compositional changes in fluid(s) on a micrometer to millimeter scale (as reflected by dolomite compositions within CI chondrites) were most likely controlled by the availability of Ca2+ Mg2+, Fe2+, and especially Mn2+ ions in the aqueous solutions, more widespread compositional changes on a meter (or even larger) scale were controlled by variable pH, Eh, CO2 partial pressure, and, especially, temperature conditions (as reflected by the compositional variability of dolomites among CIs).
Collapse
Affiliation(s)
- M Endress
- Institut fur Planetologie, Westfalische Wilhelms-Universitat Munster, Germany
| | | |
Collapse
|